mAb MDR1-modified chitosan nanoparticles overcome acquired EGFR-TKI resistance through two potential therapeutic targets modulation of MDR1 and autophagy

mAb MDR1-modified chitosan nanoparticles overcome acquired EGFR-TKI resistance through two potential therapeutic targets modulation of MDR1 and autophagy

Abstract Background Tyrosine kinase inhibitors (TKIs) that act against the epithelial growth factor receptor (EGFR) were once widely used in chemotherapy for many human cancers. However, acquired chemoresistance occurred in almost all patients, limiting the clinical application of EGFR-TKI. Thus far...

Full description

Bibliographic Details
Main Authors: Yan Zheng, Chang Su, Liang Zhao, Yijie Shi
Format: Article
Language:English
Published: BMC 2017-10-01
Series:Journal of Nanobiotechnology
Subjects:
EGFR
Tyrosine kinase inhibitor
Nanoparticles
Gefitinib
Autophagy
Chloroquine
Online Access:http://link.springer.com/article/10.1186/s12951-017-0302-5

Internet

http://link.springer.com/article/10.1186/s12951-017-0302-5

Similar Items